title: P7 peptides suppress the proliferation of K562 cells induced by basic fibroblast growth factor.
abstract: Although it has been known that basic fibroblast growth factor (bFGF) is involved in tumor progression, few studies addressed the role of bFGF in hematopoietic system malignancies including chronic myeloid leukemia (CML). An elevated level of bFGF was recently found in CML patients, and bFGF was considered to play an important role in stimulating the growth of leukemia cells. Suppression of the mitogenic activity of bFGF may contribute to CML therapy. We have previously obtained a novel bFGF-binding peptide (named P7) with strong inhibitory activity against bFGF-induced cell proliferation. In this study, we investigated the effects of P7 on the proliferation of K562 cells derived from CML. The results demonstrated that P7 inhibited bFGF-stimulated proliferation, arrested the cell cycle at the G0/G1 phase, repressed the activation of MAP kinase, reversed the effects of bFGF on cell membrane ultrastructure, and caused significant changes in the expression of proteins related to proliferation. Our results suggested that the bFGF-binding peptide may have a potential antitumor effect on CML from the point of view of targeting bFGF.
authors.affiliation: College of Life Science and Technology, Jinan University, 601 Huangpu Avenue West, Guangzhou, China 510632.
authors.forename: Cong
authors.initials: C
authors.lastname: Wang
authors.forename: Yonglin
authors.initials: Y
authors.lastname: Yu
authors.forename: Quchou
authors.initials: Q
authors.lastname: Li
authors.forename: Susu
authors.initials: S
authors.lastname: Gao
authors.forename: Xinglong
authors.initials: X
authors.lastname: Jia
authors.forename: Xilei
authors.initials: X
authors.lastname: Chen
authors.forename: Ruixue
authors.initials: R
authors.lastname: Wang
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Wenhui
authors.initials: W
authors.lastname: Wang
authors.forename: Xiaokun
authors.initials: X
authors.lastname: Li
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Wu
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D015180:Electrophoresis, Gel, Two-Dimensional; D004789:Enzyme Activation / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism / Q000473:pathology; D013058:Mass Spectrometry; D018625:Microscopy, Atomic Force; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology*; D020543:Proteome / Q000378:metabolism; D040901:Proteomics / Q000379:methods; D016601:RNA-Binding Proteins / Q000378:metabolism; D012264:Ribonucleotide Reductases / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C101633:PA2G4 protein, human; D010446:Peptide Fragments; D020543:Proteome; D016601:RNA-Binding Proteins; C419399:acetyl-phenylalanyl-threonyl-leucyl-aspartyl-alanyl-aspartyl-phenylalanine; D016222:Fibroblast Growth Factor 2; D012264:Ribonucleotide Reductases; D020928:Mitogen-Activated Protein Kinases